Restricted accessResearch articleFirst published online 2014-05
Silencing Mutant Huntingtin by Adeno-Associated Virus-Mediated RNA Interference Ameliorates Disease Manifestations in the YAC128 Mouse Model of Huntington's Disease
Huntington's disease (HD) is a fatal autosomal dominant neurodegenerative disease caused by an increase in the number of polyglutamine residues in the huntingtin (Htt) protein. With the identification of the underlying basis of HD, therapies are being developed that reduce expression of the causative mutant Htt. RNA interference (RNAi) that seeks to selectively reduce the expression of such disease-causing agents is emerging as a potential therapeutic strategy for this and similar disorders. This study examines the merits of administering a recombinant adeno-associated viral (AAV) vector designed to deliver small interfering RNA (siRNA) that targets the degradation of the Htt transcript. The aim was to lower Htt levels and to correct the behavioral, biochemical, and neuropathological deficits shown to be associated with the YAC128 mouse model of HD. Our data demonstrate that AAV-mediated RNAi is effective at transducing greater than 80% of the cells in the striatum and partially reducing the levels (∼40%) of both wild-type and mutant Htt in this region. Concomitant with these reductions are significant improvements in behavioral deficits, reduction of striatal Htt aggregates, and partial correction of the aberrant striatal transcriptional profile observed in YAC128 mice. Importantly, a partial reduction of both the mutant and wild-type Htt levels is not associated with any notable overt neurotoxicity. Collectively, these results support the continued development of AAV-mediated RNAi as a therapeutic strategy for HD.
Get full access to this article
View all access options for this article.
References
1.
AmbrosV. (2004). The functions of animal microRNAs. Nature, 431, 350–355.
2.
ArrasateM., MitraS., SchweitzerE.S., et al. (2004). Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature, 431, 805–810.
3.
AugoodS.J., FaullR.L., and EmsonP.C. (1997). Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann. Neurol., 42, 215–221.
4.
BankiewiczK.S., ForsayethJ., EberlingJ.L., et al. (2006). Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol. Ther., 14, 564–570.
5.
BatesG. (2003). Huntingtin aggregation and toxicity in Huntington's disease. Lancet, 361, 1642–1644.
6.
BennC.L., SunT., Sadri-VakiliG., et al. (2008). Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner. J. Neurosci., 28, 10720–10733.
7.
BhideP.G., DayM., SappE., et al. (1996). Expression of normal and mutant huntingtin in the developing brain. J. Neurosci., 16, 5523–5535.
8.
BoudreauR.L., MartinsI., and DavidsonB.L. (2009a). Artificial microRNAs as siRNA shuttles: Improved safety as compared with shRNAs in vitro and in vivo. Mol. Ther., 17, 169–175.
9.
BoudreauR.L., McBrideJ.L., MartinsI., et al. (2009b). Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol. Ther., 17, 1053–1063.
10.
BoudreauR.L., SpenglerR.M., and DavidsonB.L. (2011). Rational design of therapeutic siRNAs: Minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease. Mol. Ther., 19, 2169–2177.
11.
CattaneoE., ZuccatoC., and TartariM. (2005). Normal huntingtin function: An alternative approach to Huntington's disease. Nat. Rev. Neurosci., 6, 919–930.
ChristineC.W., StarrP.A., LarsonP.S., et al. (2009). Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology, 73, 1662–1669.
14.
CryanJ.F., MarkouA., and LuckiI. (2002a). Assessing antidepressant activity in rodents: Recent developments and future needs. Trends Pharmacol. Sci., 23, 238–245.
15.
CryanJ.F., PageM.E., and LuckiI. (2002b). Noradrenergic lesions differentially alter the antidepressant-like effects of reboxetine in a modified forced swim test. Eur. J. Pharmacol., 436, 197–205.
16.
DavidsonB.L., and MonteysA.M. (2012). Singles engage the RNA interference pathway. Cell, 150, 873–875.
17.
DesplatsP.A., KassK.E., GilmartinT., et al. (2006). Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease. J. Neurochem., 96, 743–757.
18.
DiFigliaM., SappE., ChaseK.O., et al. (1997). Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science, 277, 1990–1993.
19.
DiFigliaM., Sena-EstevesM., ChaseK., et al. (2007). Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc. Natl. Acad. Sci. U.S.A., 104, 17204–17209.
20.
DrouetV., PerrinV., HassigR., et al. (2009). Sustained effects of nonallele-specific Huntingtin silencing. Ann. Neurol., 65, 276–285.
21.
GrondinR., KaytorM.D., AiY., et al. (2012). Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum. Brain, 135, 1197–1209.
22.
GutekunstC.A., LiS.H., YiH., et al. (1999). Nuclear and neuropil aggregates in Huntington's disease: Relationship to neuropathology. J. Neurosci., 19, 2522–2534.
23.
HarperS.Q., StaberP.D., HeX., et al. (2005). RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. U.S.A., 102, 5820–5825.
24.
JansonC., McPheeS., BilaniukL., et al. (2002). Clinical protocol: Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum. Gene Ther., 13, 1391–1412.
25.
KordasiewiczH.B., StanekL.M., WancewiczE.V., et al. (2012). Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron, 74, 1031–1044.
26.
KrolJ., LoedigeI., and FilipowiczW. (2010). The widespread regulation of microRNA biogenesis, function and decay. Nat. Rev. Genet., 11, 597–610.
27.
LansburyP.T., and LashuelH.A. (2006). A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature, 443, 774–779.
28.
LeoneP., SheraD., McPheeS.W., et al. (2012). Long-term follow-up after gene therapy for Canavan disease. Sci. Transl. Med., 4, 165ra163.
29.
LeWittP.A., RezaiA.R., LeeheyM.A., et al. (2011). AAV2-GAD gene therapy for advanced Parkinson's disease: A double-blind, sham-surgery controlled, randomised trial. Lancet Neurol., 10, 309–319.
30.
LiuW., KenningtonL.A., RosasH.D., et al. (2008). Linking SNPs to CAG repeat length in Huntington's disease patients. Nat. Methods, 5, 951–953.
31.
LombardiM.S., JaspersL., SpronkmansC., et al. (2009). A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference. Exp. Neurol., 217, 312–319.
32.
MachidaY., OkadaT., KurosawaM., et al. (2006). rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse. Biochem. Biophys. Res. Commun., 343, 190–197.
33.
MatsuiM., and CoreyD.R. (2012). Allele-selective inhibition of trinucleotide repeat genes. Drug Discov. Today, 17, 443–450.
34.
McBrideJ.L., BoudreauR.L., HarperS.Q., et al. (2008). Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi. Proc. Natl. Acad. Sci. U.S.A., 105, 5868–5873.
35.
McBrideJ.L., PitzerM.R., BoudreauR.L., et al. (2011). Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease. Mol. Ther., 19, 2152–2162.
36.
MingozziF., and HighK.A. (2011). Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges. Nat. Rev. Genet., 12, 341–355.
37.
MittermeyerG., ChristineC.W., RosenbluthK.H., et al. (2012). Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease. Hum. Gene Ther., 23, 377–381.
38.
PassiniM.A., and WolfeJ.H. (2001). Widespread gene delivery and structure-specific patterns of expression in the brain after intraventricular injections of neonatal mice with an adeno-associated virus vector. J. Virol., 75, 12382–12392.
39.
PfisterE.L., KenningtonL., StraubhaarJ., et al. (2009). Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr. Biol., 19, 774–778.
40.
PorsoltR.D., BertinA., and JalfreM. (1977). Behavioral despair in mice: A primary screening test for antidepressants. Arch. Int. Pharmacodyn. Ther., 229, 327–336.
41.
PouladiM.A., GrahamR.K., KarasinskaJ.M., et al. (2009). Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain, 132, 919–932.
42.
PouladiM.A., StanekL.M., XieY., et al. (2012). Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice. Hum. Mol. Genet., 21, 2219–2232.
43.
ReinerA., DragatsisI., ZeitlinS., and GoldowitzD. (2003). Wild-type huntingtin plays a role in brain development and neuronal survival. Mol. Neurobiol., 28, 259–276.
44.
RichfieldE.K., Maguire-ZeissK.A., CoxC., et al. (1995). Reduced expression of preproenkephalin in striatal neurons from Huntington's disease patients. Ann. Neurol., 37, 335–343.
45.
Rodriguez-LebronE., Denovan-WrightE.M., NashK., et al. (2005). Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol. Ther., 12, 618–633.
46.
RosasH.D., LiuA.K., HerschS., et al. (2002). Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology, 58, 695–701.
47.
SahD.W., and AroninN. (2011). Oligonucleotide therapeutic approaches for Huntington disease. J. Clin. Invest., 121, 500–507.
48.
SaudouF., FinkbeinerS., DevysD., and GreenbergM.E. (1998). Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell, 95, 55–66.
49.
SchaffarG., BreuerP., BotevaR., et al. (2004). Cellular toxicity of polyglutamine expansion proteins: Mechanism of transcription factor deactivation. Mol. Cell, 15, 95–105.
50.
ScherzingerE., LurzR., TurmaineM., et al. (1997). Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell, 90, 549–558.
51.
SeyhanA.A. (2011). RNAi: A potential new class of therapeutic for human genetic disease. Hum. Genet., 130, 583–605.
52.
SlowE.J., van RaamsdonkJ., RogersD., et al. (2003). Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum. Mol. Genet., 12, 1555–1567.
53.
SugarsK.L., BrownR., CookL.J., et al. (2004). Decreased cAMP response element-mediated transcription: An early event in exon 1 and full-length cell models of Huntington's disease that contributes to polyglutamine pathogenesis. J. Biol. Chem., 279, 4988–4999.
54.
van BilsenP.H., JaspersL., LombardiM.S., et al. (2008). Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts. Hum. Gene Ther., 19, 710–719.
55.
Van RaamsdonkJ., MurphyJ.M., SlowE., et al. (2005). Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. Hum. Mol. Genet., 14, 3823–3835.
56.
Van RaamsdonkJ.M., MetzlerM., SlowE., et al. (2007). Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain. Neurobiol. Dis., 26, 189–200.
57.
VonsattelJ.P., MyersR.H., StevensT.J., et al. (1985). Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol., 44, 559–577.
58.
WangY.L., LiuW., WadaE., et al. (2005). Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA. Neurosci. Res., 53, 241–249.
59.
WinerJ., JungC.K.S., ShackelI., WilliamsP.M. (1999). Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Analytical Biochemistry, 270, 41–49.
60.
YamamotoA., LucasJ.J., and HenR. (2000). Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell, 101, 57–66.
61.
YuD., PendergraffH., LiuJ., et al. (2012). Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell, 150, 895–908.
62.
ZuccatoC., TartariM., CrottiA., et al. (2003). Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat. Genet., 35, 76–83.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
